We will have limited operations from 15:00 Tuesday 24 December 2024 (AEDT) until Thursday 2 January 2025. Find out how to contact us during the holiday period.
Results for
"[search-keyword]"
Sponsor content
52 result(s) found, displaying 1 to 10
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for OMLYCLO omalizumab (rch) 75 mg/0.5 mL solution for injection in a pre-filled syringe with needle guard.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for OMLYCLO omalizumab (rch) 150 mg/ mL solution for injection in a pre-filled syringe with needle guard.
-
Prescription medicine decision summarySteqeyma (ustekinumab) has been approved to treat moderate to severe plaque psoriasis, active psoriatic arthritis, crohn's disease, and ulcerative colitis.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for YUFLYMA adalimumab (rch) 20 mg/0.2 mL solution for injection pre-filled syringe.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for STEQEYMA ustekinumab 90mg/1 mL solution for injection pre-filled syringe with safety guard.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for STEQEYMA ustekinumab 130 mg/26 mL concentrate for solution for infusion vial.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for STEQEYMA ustekinumab 45 mg/0.5 mL solution for injection pre-filled syringe with safety guard.
-
Prescription medicine registrationActive ingredients: Ustekinumab.
-
Australian Public Assessment Report (AusPAR)Vegzelma (bevacizumab), in combination with fluoropyrimidine-based chemotherapy, has been approved for the treatment of metastatic colorectal cancer.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for VEGZELMA bevacizumab 100 mg/ 4 mL solution for intravenous infusion, vial.